BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36735076)

  • 1. Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia.
    Sun Y; Wang Q; Zhang X; Zhang Z; Wang Q; Cen J; Zhu M; Pan J; Liu D; Wu D; Cai Y; Chen S
    Ann Hematol; 2023 Apr; 102(4):777-785. PubMed ID: 36735076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.
    Itonaga H; Ota S; Ikeda T; Taji H; Amano I; Hasegawa Y; Ichinohe T; Fukuda T; Atsuta Y; Tanizawa A; Kondo T; Miyazaki Y
    Leuk Res; 2018 Dec; 75():50-57. PubMed ID: 30458320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Onida F; de Wreede LC; van Biezen A; Eikema DJ; Byrne JL; Iori AP; Schots R; Jungova A; Schetelig J; Finke J; Veelken H; Johansson JE; Craddock C; Stelljes M; Theobald M; Holler E; Schanz U; Schaap N; Bittenbring J; Olavarria E; Chalandon Y; Kröger N
    Br J Haematol; 2017 Jun; 177(5):759-765. PubMed ID: 28369779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
    Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The occurrence of Philadelphia chromosome (Ph) negative leukemia after hematopoietic stem cell transplantation for Ph positive chronic myeloid leukemia: implications for disease monitoring and treatment.
    Au WY; Ma SK; Kwong YL
    Leuk Lymphoma; 2003 Jul; 44(7):1121-9. PubMed ID: 12916863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
    Tachibana T; Kondo T; Uchida N; Doki N; Takada S; Takahashi S; Yano S; Mori T; Kohno A; Kimura T; Fukuda T; Atsuta Y; Nagamura-Inoue T;
    Transplant Cell Ther; 2022 Jun; 28(6):321.e1-321.e8. PubMed ID: 35296447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I treat atypical chronic myeloid leukemia.
    Gotlib J
    Blood; 2017 Feb; 129(7):838-845. PubMed ID: 27899359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
    Egan DN; Beppu L; Radich JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical Chronic Myeloid Leukemia: Where Are We Now?
    Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
    Saxena K; Jabbour E; Issa G; Sasaki K; Ravandi F; Maiti A; Daver N; Kadia T; DiNardo CD; Konopleva M; Cortes JE; Yilmaz M; Chien K; Pierce S; Kantarjian H; Short NJ
    J Hematol Oncol; 2021 Jun; 14(1):94. PubMed ID: 34130720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
    Cheng J; Liao Y; Bin T; OUYang J; Chen S; Chen X; Zou W
    Curr Med Res Opin; 2020 Nov; 36(11):1807-1812. PubMed ID: 32936052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
    Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
    Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
    Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical CML: diagnosis and treatment.
    Breccia M
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and evolving understanding of atypical chronic myeloid leukemia.
    Schwartz LC; Mascarenhas J
    Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.